Wockhardt To Launch Its Zaynich Antibiotic Drug in Europe and USA

Mumbai | June 6, 2025 – Pharma major Wockhardt Ltd has announced plans to enter the $7 billion US and European markets with its new antibiotic Zaynich, aimed at treating gram-negative infections. Regulatory filings are expected to begin in FY2026-27, following a successful pre-NDA meeting with the USFDA in May 2025. A formal submission is scheduled for Q2 FY25.

The company also plans to seek European and emerging market approvals in the second half of FY2025, with an Indian launch depending on clearance from the Drug Controller General of India (DCGI). In 2024, Wockhardt announced plans to launch its novel antibiotic candidate, WCK 5222 (Zaynich), in India by the end of fiscal year 2024-25, with a global rollout scheduled for 2025-26. The antibiotic is expected to address a global market valued at around $25 billion. The company estimated the market potential for this product in India at ₹17,000 crore, while the opportunity in the US and Europe was valued at approximately $7 billion. Zaynich could potentially treat over 11 lakh cases annually in India alone.

Financially, Wockhardt significantly reduced its consolidated Q4 FY25 net loss to ₹45 crore, down from ₹177 crore in Q4 FY24. Quarterly revenue increased to ₹743 crore from ₹700 crore year-on-year. For the full year, the net loss narrowed to ₹57 crore, compared to ₹472 crore in FY24, while revenue rose to ₹3,012 crore from ₹2,798 crore.

What Led Up to This Announcement?

• Wockhardt spent over 14 years developing Zaynich, marking the first end-to-end novel antibiotic discovery and development by an Indian company targeting global markets.
• Pivotal Phase III trials showed Zaynich achieved 96.8–98% efficacy against serious gram-negative infections, including carbapenem-resistant cases.
• The drug outperformed the standard antibiotic meropenem in clinical trials.
• Zaynich demonstrated 100% cure rates in bloodstream infections, ventilator-associated pneumonia, and intra-abdominal infections.
• Wockhardt aligned its clinical trial endpoints with USFDA and EMA requirements to meet global regulatory standards.
• The company established susceptibility breakpoints for multi-resistant gram-negative pathogens.
• Compassionate use of Zaynich was authorised to treat critically ill patients before formal approval, supporting real-world safety data.

Market & Industry Context

• Global antibiotics market: Valued between $50–53 billion in 2023–24, and growing at 4–5% CAGR, potentially reaching $68–86 billion by 2027–2033 .
• Europe: The antibiotics market was estimated at $10.9–11.3 billion in 2023–24, with a steady 3–3.3% CAGR forecast to 2030 .
• Unmet need: Rising global antimicrobial resistance (AMR) — with ~5 million deaths linked to AMR yearly and increasing multidrug-resistant gram-negative infections – underscores urgent demand for new treatments

Strategic Significance

Breakthrough for Indian Pharma: Wockhardt’s Zaynich is India’s first fully in-house novel antibiotic targeting drug-resistant gram-negative bacteria, marking a major innovation milestone and positioning the company as a global antibiotic pioneer.

Global Anti-Infective Shift: Moving beyond generics, Wockhardt enters the lucrative anti-infective market in the US and Europe, enhancing credibility and unlocking potential for partnerships and premium pricing.

Regulatory Confidence: The recent pre-NDA USFDA meeting highlights strong regulatory readiness. Possible Fast Track or QIDP status could grant extended market exclusivity, speeding up launch and attracting investors.

Global Launch Strategy: Wockhardt plans launches across the US, Europe, India, and emerging markets — balancing premium pricing, volume demand, and significant domestic patient numbers (11 lakh annually).

Industry Tailwinds: Zaynich’s launch aligns with the urgent global focus on antimicrobial resistance (AMR), benefiting from supportive policies and growing hospital demand for new antibiotics.

Financial Growth Potential: With a $7 billion global antibiotic market and limited competition, Zaynich can drive significant revenue growth and help Wockhardt improve profitability.

Strong IP Protection: Patents and regulatory exclusivity will protect Zaynich for 7–10 years, creating a competitive moat against generics and ensuring revenue stability.

Wockhardt’s Recent Launches and Diabetes Growth Plans

Wockhardt has recently launched the antibiotic Miqnaf (nafithromycin) in India, targeting respiratory tract infections. The company estimates this market opportunity at ₹10,800 crore.

In the diabetes segment, Wockhardt highlighted a significant opportunity following Novo Nordisk’s exit from the human disposable insulin pens and cartridges market. As one of only three companies addressing this space, Wockhardt sees a potential $157 million market in emerging markets.

The company believes it is “uniquely positioned” to serve the broader diabetes segment, which represents a $3 billion opportunity in emerging markets. To capitalise on this, Wockhardt is doubling its production capacity over the next three years, aiming for growth of around 20-25%.

Outlook & Future Perspective

• Regulatory timeline: USFDA NDA expected Q2 FY26; EU approvals and emerging markets filings set for H2 FY25, aligning with global launch strategy.
• Market launch windows: FY2026-27 commercial debut in US/EU; concurrent rollout in India pending DCGI approval.
• Growth projection: If Zaynich captures even 10–15% of its $7 billion addressable market, revenues could hit $700–1,050 million annually, dwarfing Wockhardt’s FY25 revenues (₹3,012 crore, $360 million).

Disclaimer:  At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.

If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.

Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations